The Prognostic Value of the Expression of SMC4 mRNA in Breast Cancer
Table 1
The relationship between SMC4 expression and clinicopathological characteristics in female breast cancer patients from the TCGA cohort enrolled from 2001 to 2013 ().
Clinicopathological characteristic
Low SMC4 (%) ()
High SMC4 (%) ()
Age
2.465
0.117
≤65
428 (60.4%)
281 (39.6%)
>65
186 (65.7%)
97 (34.3%)
Menopause
2.165
0.141
Premenopause
146 (57.5%)
108 (42.5%)
Postmenopause
387 (62.8%)
229 (37.2%)
Tumor categories
8.993
0.003
T1
181 (69.6%)
79 (30.4%)
T2-T4
432 (59.1%)
299 (40.9%)
Lymph node metastasis
1.359
0.244
None
289 (59.8%)
194 (40.2%)
Present
166 (31.6%)
227 (18.2%)
Distant metastasis
0.077
0.781
No
489 (59.1%)
339 (40.9%)
Yes
10 (62.5%)
6 (37.5%)
Clinical stage
1.954
0.162
I-II
449 (60.7%)
291 (39.3%)
III-IV
159 (65.7%)
83 (34.3%)
Estrogen receptor
71.256
<0.001
Negative
80 (37.4%)
134 (62.6%)
Positive
508 (69.2%)
226 (30.8%)
Progesterone receptor
58.413
<0.001
Negative
141 (44.9%)
173 (55.1%)
Positive
445 (70.5%)
186 (29.5%)
HER-2
0.036
0.849
Negative
457 (62.1%)
279 (37.9%)
Positive
111 (61.3%)
70 (38.7%)
TNBC
72.197
<0.001
Yes
50 (32.1%)
106 (67.9%)
No
517 (68.3%)
240 (31.7%)
HER-2 = human epidermal growth factor receptor 2; TNBC = triple negative breast cancer; SMC4 = structural maintenance of chromosomes protein 4 mRNA.
